Intellia Therapeutics, Inc.
Net SellingNTLA·US·🇺🇸 US
8%buys·92%sells
830 transactions$69.5MTotal buys·25 buys
$344.0MTotal sells·280 sells
5050 insiders
Last: Dec 12, 2025
| Date | Insider | Type | Value | |
|---|---|---|---|---|
| Dec 12, 25 | LEONARD JOHN M. | Exercise | - | |
| Dec 12, 25 | LEONARD JOHN M. | Exercise | $58K | |
| Dec 11, 25 | LEONARD JOHN M. | Exercise | - | |
| Dec 11, 25 | LEONARD JOHN M. | Sell | $474K | |
| Dec 11, 25 | LEONARD JOHN M. | Sell | $311K | |
| Dec 11, 25 | LEONARD JOHN M. | Sell | $51K | |
| Dec 11, 25 | LEONARD JOHN M. | Exercise | $341K | |
| Oct 1, 25 | Dube Michael P | Sell | $33K | |
| Oct 1, 25 | Schultes Birgit C | Sell | $539 | |
| Aug 20, 25 | CHASE WILLIAM J | Buy | $1.0M |
LEONARD JOHN M. (CEO) recently executed a sell of $474K in Intellia Therapeutics, Inc. shares on December 11, 2025. Overall insider sentiment is bearish (92% sales).
Intellia Therapeutics, Inc. (NTLA) has recorded 830 insider operations, including 25 open-market purchases ($69.5M), 280 sales ($344.0M) and 525 other operations (stock option exercises, grants, tax dispositions, donations). The insider sentiment is bearish (92% sales).
Insider activity at Intellia Therapeutics, Inc. is sustained, with operations recorded in 8 of the last 12 months — a sign of regular regulatory filings.
Among the most active insiders are LEONARD JOHN M. (CEO), Bermingham Nessan (CEO) & Goddard Glenn (CFO), with respectively 194, 26, 158 transactions.
Across all 830 recorded transactions, the breakdown by type is: exercise (288, 35%), sells (280, 34%), grant (232, 28%), buys (25, 3%), other (5, 1%).
Data sourced from regulatory filings (SEC Form 4, AMF, BaFin, FI, and other European authorities).
Intellia Therapeutics, Inc. has recorded 830 insider operations in total, including 25 open-market purchases ($69.5M), 280 sales ($344.0M) and 525 other operations (stock option exercises, grants, tax dispositions, donations). The most recent transaction was recorded on December 12, 2025.
Insiders at Intellia Therapeutics, Inc. are currently net sellers, with 8% purchases and 92% sales across all reported transactions. Total buy volume is $69.5M versus $344.0M in sales, indicating a bearish insider sentiment.
InsiderLens tracks 50 insiders at Intellia Therapeutics, Inc. (NTLA). LEONARD JOHN M. (CEO, 194 tx), Bermingham Nessan (CEO, 26 tx), Goddard Glenn (CFO, 158 tx). Data is sourced from mandatory regulatory filings for persons with access to privileged information.
The insider signal for NTLA is bearish, based on a 8% buy ratio across 305 buy and sell transactions reported to financial regulators. Transactions from C-suite executives (CEO, CFO) and board members are generally considered the most informative signals.
Insider trading data for Intellia Therapeutics, Inc. comes from official regulatory filings: SEC Form 4 (United States), AMF (France), BaFin (Germany), FI (Sweden), and other European financial authorities. These filings are mandatory for directors, officers, and holders of more than 10% of a company's shares. InsiderLens aggregates and normalizes this data for analysis.